Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus? (A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial)

oa Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus? (A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial)
By Vasilios G. Athyros, Niki Katsiki and Nikolaos Tentolouris
Source: Current Vascular Pharmacology, Volume 14, Issue 5, Sep 2016, p. 469 - 473
DOI: https://doi.org/10.2174/1570161114666160909161537
- Available online: 01 Sep 2016

There is no abstract available.

Article metrics loading...

/content/journals/cvp/10.2174/1570161114666160909161537

2016-09-01

2025-10-14

Full text loading...

/content/journals/cvp/10.2174/1570161114666160909161537

Keyword(s): cardiovascular disease; dipeptidyl peptidase 4 inhibitors; Glucagon-like-peptide-1 receptor agonists; heart failure; type 2 diabetes mellitus

oa Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus? (A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial)